Mentions
Extended reach
Total likes
Video views
AI synopsis
Many mentions, such as the Bioengineering blog and scientific articles, express strong agreement with the significance of disitamab vedotin's promising trial results. The tone is enthusiastic, with references to reshaping treatment and survival benefits, supporting high interest and impact; the detailed discussion of trial data and implications signifies deep engagement.
Most mentions highlight the positive results of the phase 3 trial and the potential of disitamab vedotin, indicating strong overall agreement with the article's findings.
The mentions frequently emphasize new treatment options and clinical trial results, which suggest high public and scientific interest.
Discussions include details about trial data, mechanisms, and significance, showing deep engagement.
Mentions discuss how the drug could reshape treatment for HER2-positive breast cancer with liver metastases, indicating high impact.
Disitamab Vedotin significantly improved progression-free survival in HER2-positive breast cancer patients with liver metastases, showing a median PFS of 9.9 months compared to 4.9 months with lapatinib plus…
Qingyuan Zhang's 475 research items with 14770 citations and 3184 reads, including: Disitamab vedotin for HER2-positive breast cancer with liver metastases: ...
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial · Article · Full-text available.
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial. Article. Full-text available. Aug ...
... y del receptor del factor de crecimiento epidérmico (EGFR), es activo ... https://doi.org/10.1038/s41467-026-75733-y · Crossref. Kathrine Vandraas,; Bjørn ...
Das berichtet eine chinesische Arbeitsgruppe in der Fachzeitschrift Nature Communications (2026, DOI: 10.1038/s41467-026-75733-y).
https://doi.org/10.1038/s41467-026-75733-y. Image Credits: AI Generated. DOI: 10.1038/s41467-026-75733-y. Keywords: disitamab vedotin, HER2 ...
... Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial Journal: Nature ...
Article: Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3... Breast Cancer -- see more articles. Reference ...
Article: Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3... Article: Comparison of Remimazolam and Propofol ...
https://doi.org/10.1038/s41467-026-75733-y · Crossref. Kathrine Vandraas,; Bjørn Naume,; Anna Sætersdal,; Egil Blix,. HER2-positiv brystkreft ...